



Lipid-based Nanoparticle Systems for Drug Delivery

Guest Editors:

Prof. Dr. Aleksander F. Sikorski

Research and Development
Centre, Regional Specialist
Hospital in Wrocław,
Kamieńskiego 73a, 51-124
Wrocław, Poland

Prof. Dr. Marek Langner

Department of Biomedical
Engineering, Faculty of
Fundamental Problems of
Technology, Wrocław University
of Science and Technology, Pl.
Grunwaldzki 13, 50-377 Wrocław,
Poland

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editors

Dear Colleagues,

Nanocarrier technology in drug delivery research has achieved reasonable success in the development of modern therapies, permitting better bioavailability and pharmacodynamics, as well as reducing side effects and providing the possibility of specific targeting of the drug. In particular, due to their biocompatibility and flexibility, supramolecular lipid-aggregate-based nanocarriers, such as lipid nanoparticles, liposomes, nanoemulsions, and micelles, have been the subjects of extensive studies that resulted in several technologies and commercially available therapeutics, including Ambisome, Doxil or recently registered ONPATTRO (patísiran). These seem to be only a small fraction of the opportunities provided by the system built from naturally occurring lipids and similar non-toxic organic compounds. No commercial lipid-based preparation has explored the possibility of targeting the diseased site in the body with lipid aggregate-packed drugs. Hereby, we invite all researchers to contribute to this Special Issue, which will collect review articles devoted to various aspects of lipid aggregate-based drug nanocarrier studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma